{"type": "root", "children": [{"type": "p", "children": [{"type": "t", "text": "\nRecent findings demonstrate that the long non‐coding RNA PTOV1‑AS1 is significantly upregulated in hepatocellular carcinoma (HCC) tissues compared to normal counterparts, an alteration that correlates with poorer overall survival in patients. Functional studies revealed that silencing PTOV1‑AS1 in HCC cells markedly suppresses proliferation, invasion, and notably reverses sorafenib resistance in cell lines such as HepG2-SR and Huh7-SR. Mechanistically, PTOV1‑AS1 acts by negatively regulating miR‑505 expression, indicating that this lncRNA promotes tumor aggressiveness and chemoresistance by modulating miRNA networks. These insights suggest that targeting PTOV1‑AS1 may offer new therapeutic avenues to overcome sorafenib resistance in HCC."}, {"type": "fg", "children": [{"type": "fg_f", "ref": "1"}]}, {"type": "t", "text": ""}]}, {"type": "rg", "children": [{"type": "r", "ref": 1, "children": [{"type": "t", "text": "Xiaobin Chi, Zhijian Chen, Yongbiao Chen, et al. "}, {"type": "b", "children": [{"type": "t", "text": "Upregulation of lncRNA PTOV1-AS1 in hepatocellular carcinoma contributes to disease progression and sorafenib resistance through regulating miR-505."}]}, {"type": "t", "text": " "}, {"type": "i", "children": [{"type": "t", "text": "J Biochem Mol Toxicol (2023)"}]}, {"type": "t", "text": " DOI: "}, {"type": "a", "children": [{"type": "t", "text": "10.1002/jbt.23437"}], "href": "https://doi.org/10.1002/jbt.23437"}, {"type": "t", "text": " PMID: "}, {"type": "a", "children": [{"type": "t", "text": "37352125"}], "href": "https://pubmed.ncbi.nlm.nih.gov/37352125"}]}]}]}